Cell line · CVCL_1700
Papers84
1 more article gives this line's RRID in its Methods without naming the line nearby, so it is not listed.
1 to 20 of 84
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| RAS inhibition limits oncogenic signaling and tumorigenesis in neuroblastoma regardless of RAS mutational status | Sci Rep | 2026 | Its Methods give the RRID and name the line | PubMed | |
| LGALS3BP is associated with selective cargo enrichment in neuroblastoma extracellular vesicles. | Front Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PP2A Activation as a Senotherapeutic in Neuroblastoma. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Calu-3 cells as novel efficient cell culture system for Borna disease virus 1 (BoDV-1). | Virus Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Multi‑omics identification of MSI2 as a super-enhancer‑driven vulnerability in MYCN‑amplified neuroblastoma. | J Transl Med | 2026 | Its Methods give the RRID and name the line | PubMed | |
| USP29-regulated noncanonical stabilization of the hypoxia-inducible factor-α in aggressive prostate cancer. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Sialic acid cis-ligand dynamics modulate Siglec-7 and -9 function and affect Siglec-7/9 co-blockade to potentiate natural killer cell anti-tumor activity. | Oncoimmunology | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Functional profiling of somatostatin receptors identifies somatostatin receptor subtype 2 as a vulnerability in Succinate Dehydrogenase SDHB-deficient pheochromocytomas and paragangliomas. | Mol Biomed | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DNA-PKcs promotes therapy resistance and metastatic recurrence in neuroblastoma. | Cancer Lett | 2026 | Its Methods give the RRID and name the line | PubMed | |
| YAP1 Enhances Mesenchymal-Type Gene Expression in Human Adrenergic-Type Neuroblastoma Cells. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Defining the Functional Role and Potential as an Immunotherapeutic Target of ALCAM in Neuroblastoma. | Mol Cancer Ther | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Glycosylated LGALS3BP is highly secreted by bladder cancer cells and represents a novel urinary disease biomarker. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| D3-GPC2-Directed CAR T Cells Are Safe and Efficacious in Preclinical Models of Neuroblastoma and Small Cell Lung Cancer. | Clin Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeted inhibition of WIP1 and histone H3K27 demethylase activity synergistically suppresses neuroblastoma growth. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Serially Quantifying TERT Rearrangement Breakpoints in ctDNA Enables Minimal Residual Disease Monitoring in Patients with Neuroblastoma. | Cancer Res Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Transcription factor 4 is a key mediator of oncogenesis in neuroblastoma by promoting MYC activity. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Combined inhibition of histone methyltransferases EZH2 and DOT1L is an effective therapy for neuroblastoma. | Cancer Med | 2024 | Its Methods give the RRID and name the line | PubMed | |
| B7-H3-Targeted CAR-Vδ1T Cells Exhibit Potent Broad-Spectrum Activity against Solid Tumors. | Cancer Res | 2024 | Its Methods give the RRID and name the line | PubMed | |
| Integrated machine learning-driven disulfidptosis profiling: CYFIP1 and EMILIN1 as therapeutic nodes in neuroblastoma. | J Cancer Res Clin Oncol | 2024 | Its Methods give the RRID and name the line | PubMed | |
| The Oncolytic Activity of Zika Viral Therapy in Human Neuroblastoma In Vivo Models Confers a Major Survival Advantage in a CD24-dependent Manner. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_1700/papers